Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target Cut to $3.50 by Analysts at HC Wainwright

Adaptimmune Therapeutics (NASDAQ:ADAP) had its price objective trimmed by HC Wainwright from $4.00 to $3.50 in a research report released on Thursday,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Adaptimmune Therapeutics’ Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.12) EPS.

Separately, StockNews.com upgraded Adaptimmune Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 13th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $3.16.

Adaptimmune Therapeutics Price Performance

Shares of NASDAQ ADAP opened at $0.59 on Thursday. The company has a quick ratio of 3.09, a current ratio of 3.09 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $150.02 million, a PE ratio of -2.67 and a beta of 2.26. The stock’s 50 day moving average price is $0.88 and its 200-day moving average price is $1.03. Adaptimmune Therapeutics has a twelve month low of $0.42 and a twelve month high of $2.05.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Large investors have recently modified their holdings of the stock. Long Focus Capital Management LLC lifted its stake in Adaptimmune Therapeutics by 15.6% in the second quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company’s stock valued at $12,037,000 after purchasing an additional 1,662,184 shares during the last quarter. Baillie Gifford & Co. raised its stake in shares of Adaptimmune Therapeutics by 10.7% in the third quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock valued at $15,944,000 after buying an additional 1,626,657 shares during the period. Renaissance Technologies LLC lifted its position in shares of Adaptimmune Therapeutics by 28.3% during the 2nd quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock valued at $1,742,000 after buying an additional 394,566 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Adaptimmune Therapeutics during the 3rd quarter valued at $95,000. Finally, Jane Street Group LLC grew its stake in shares of Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 98,581 shares during the period. Hedge funds and other institutional investors own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.